# Serplulimab for Locally Advanced Cervical Cancer

> **NCT07340489** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 216 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Serplulimab
- **RADIATION:** radiotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07340489
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340489, "Serplulimab for Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07340489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*